BioCryst制药 BCRX 深 沪
已收盘 12-19 16:00:00 美东时间
7.415
+0.125
+1.71%
华盛通- 最 高8.17
- 今 开7.24
- 成交量 321.69万股
- 最 低 6.705
- 昨 收 7.29
- 总市值 13.79亿
- 52周最高 11.31
- 市盈率 静 --
- 换手率 1.73%
- 52周最低 6.00
- 委 比 -67.92%
- 总股本 1.86亿
- 历史最高 19.99
- 量 比 0.82
- 振 幅 20.10%
- 历史最低 1.08
- 每 手 1
- 风险率 1.11%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Top Stocks With Earnings This Week: Joby, IonQ, AMD and More
Retail investors are preparing for another busy week of earnings season with more than 1,600 companies set to report through Friday.
11-03 22:14
BioCryst Pharma Raises FY2025 Sales Guidance from $580.000M-$600.000M to $590.000M-$600.000M vs $625.558M Est
BioCryst Pharma (NASDAQ:BCRX) raises FY2025 sales outlook from $580.000 million-$600.000 million to $590.000 million-$600.000 million vs $625.558 million estimate.
11-03 20:01
Earnings Scheduled For November 3, 2025
Companies Reporting Before The Bell • CNA Financial (NYSE:CNA) is expected to r...
11-03 19:11
BioCryst Presents New Data on the Long-term Efficacy and Safety of ORLADEYO® (berotralstat) Across all Ages at EAACI
New data from BioCryst Pharmaceuticals highlights that ORLADEYO significantly reduces hereditary angioedema (HAE) attacks across all age groups, with sustained safety and improved quality of life for patients. Studies show a substantial decrease in attack frequency and severity, alongside minimal adverse effects, further validating ORLADEYO as a long-term prophylactic treatment option.
06-16 11:00
ORLADEYO® (berotralstat) Approved in Colombia
BioCryst Pharmaceuticals announced that ORLADEYO, an oral once-daily therapy for hereditary angioedema (HAE), has been approved in Colombia for adult and pediatric patients aged 12 or older. The drug works by inhibiting plasma kallikrein and has been previously approved in other Latin American countries.
06-13 11:00
BioCryst Achieves Reimbursement for ORLADEYO Across all Major European Countries
BioCryst announced that ORLADEYO, the first oral, once-daily preventive therapy for hereditary angioedema (HAE), has been approved for reimbursement in the Netherlands. This marks national reimbursement across all major European countries, providing HAE patients access to the first oral preventive therapy.
06-06 11:00
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BioCryst Pharmaceuticals授予七名新员工总计47,250股的限制性股票单位（RSUs），作为雇佣激励，股票分四年归属，且需满足服务条件。BioCryst是一家专注于罕见病治疗的全球生物技术公司，已商业化口服药物ORLADEYO®，并推进多款候选药物的开发。
06-03 11:00
BioCryst to Present New Data at 2025 Meeting of the European Academy of Allergy and Clinical Immunology
<p><p align="justify">BioCryst Pharmaceuticals will present new data on ORLADEYO<sup>®</sup>, an oral treatment for hereditary angioedema (HAE), at the EAACI meeting in Glasgow. Four abstracts highlight its effectiveness, patient experiences, and impact on reducing HAE attacks, including interim results from pediatric trials. ORLADEYO is the first oral therapy for HAE prophylaxis in adults and adolescents.</p>
06-02 11:00
BioCryst Highlights Real-world Data Showing ORLADEYO® (berotralstat) Consistently Reduces HAE Attacks Across All Ages
New data presented highlights the effectiveness of berotralstat in reducing HAE symptoms across all age groups, including young children, with sustained benefits and a favorable safety profile.
05-30 11:00
BioCryst to Present at Upcoming Investor Conferences
BioCryst Pharmaceuticals plans to attend healthcare conferences on June 4 and 9, 2025.
05-27 11:00
